AIMD
AIMD 1-star rating from Upturn Advisory

Ainos Inc (AIMD)

Ainos Inc (AIMD) 1-star rating from Upturn Advisory
$1.63
Last Close (24-hour delay)
upturn advisory logo
PASS
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

02/24/2026: AIMD (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Advertisement

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 10.48M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 2.22
52 Weeks Range 0.40 - 2.60
Updated Date 06/29/2025
52 Weeks Range 0.40 - 2.60
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -6
Advertisement

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2978.02%

Management Effectiveness

Return on Assets (TTM) -30.93%
Return on Equity (TTM) -82.87%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 61772226
Price to Sales(TTM) 98.68
Enterprise Value 61772226
Price to Sales(TTM) 98.68
Enterprise Value to Revenue 581.62
Enterprise Value to EBITDA -1.6
Shares Outstanding 20960200
Shares Floating 9206027
Shares Outstanding 20960200
Shares Floating 9206027
Percent Insiders 65.58
Percent Institutions 0.55

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI SWOT

Ainos Inc

Ainos Inc(AIMD) company logo displayed in Upturn AI summary

Company Overview

Company history and background logo History and Background

Ainos Inc. (formerly HealthSpot, Inc.) has undergone significant transformation. It was founded with the aim of providing innovative healthcare solutions. The company has pivoted its focus and strategy multiple times, most recently towards telehealth and digital health services, aiming to capitalize on the growing demand for remote patient care and chronic disease management.

Company business area logo Core Business Areas

  • Telehealth Platform: Development and operation of a proprietary telehealth platform designed to connect patients with healthcare providers remotely. This includes features for virtual consultations, remote monitoring, and patient engagement.
  • Digital Health Solutions: Offering a suite of digital health solutions aimed at improving patient outcomes and operational efficiency for healthcare providers. This may include data analytics, AI-driven insights, and personalized care plans.

leadership logo Leadership and Structure

Ainos Inc. is led by a management team responsible for strategic direction and operational execution. The organizational structure is likely to be aligned with its core business areas, with teams focused on technology development, sales and marketing, clinical operations, and corporate functions. Specific leadership roles and detailed organizational charts are typically found in the company's investor relations materials.

Top Products and Market Share

Product Key Offerings logo Key Offerings

  • Telehealth Platform: Ainos' telehealth platform aims to provide a comprehensive solution for remote healthcare delivery. While specific market share data for Ainos' platform is not readily available due to its evolving nature and the fragmented telehealth market, competitors include established players like Teladoc Health (TDOC), Amwell (AMWL), and numerous smaller, specialized providers. Revenue figures for this segment would be reported in the company's financial statements.
  • Remote Patient Monitoring (RPM) Solutions: This encompasses devices and software for patients to monitor their vital signs and health metrics from home, with data transmitted to healthcare providers. Competitors in this space include Philips Healthcare, Medtronic, and various IoT health device manufacturers. Market penetration and revenue generated by Ainos' specific RPM offerings would be detailed in their financial reports.

Market Dynamics

industry overview logo Industry Overview

The telehealth and digital health industry is experiencing rapid growth, driven by increasing adoption of virtual care, the need for convenient and accessible healthcare, advancements in technology, and government initiatives supporting digital health. The market is characterized by intense competition, ongoing innovation, and a focus on improving patient outcomes and cost-effectiveness.

Positioning

Ainos Inc. aims to position itself as a provider of integrated telehealth and digital health solutions, focusing on underserved patient populations or specific chronic disease management areas. Its competitive advantage may lie in its proprietary technology, strategic partnerships, or specialized service offerings. However, as a smaller player, it faces significant competition from larger, well-established companies with broader reach and resources.

Total Addressable Market (TAM)

The global digital health market is projected to reach hundreds of billions of dollars in the coming years, with telehealth and remote patient monitoring being significant sub-segments. Ainos Inc. is positioned to capture a portion of this TAM by offering its platform and solutions, but its market share will depend on its ability to scale, acquire users, and demonstrate value to both patients and providers in a competitive landscape.

Upturn SWOT Analysis

Strengths

  • Focus on a growing market (telehealth, digital health)
  • Potential for proprietary technology and innovation
  • Agility as a smaller company to adapt to market changes

Weaknesses

  • Limited brand recognition and market penetration compared to larger competitors
  • Potential reliance on third-party integrations or technology
  • Financial resources may be constrained for significant growth initiatives

Opportunities

  • Increasing demand for remote and chronic disease management
  • Partnerships with healthcare systems and payers
  • Expansion into new geographic markets or specialized healthcare niches
  • Advancements in AI and data analytics for personalized care

Threats

  • Intense competition from established and emerging players
  • Evolving regulatory landscape for telehealth and data privacy
  • Cybersecurity risks and data breaches
  • Challenges in user adoption and patient engagement

Competitors and Market Share

Key competitor logo Key Competitors

  • Teladoc Health (TDOC)
  • Amwell (AMWL)
  • Doctor on Demand
  • MDLive

Competitive Landscape

Ainos Inc. operates in a highly competitive telehealth and digital health market. Its advantages might lie in its focused approach to specific patient needs or technological innovation. However, it faces disadvantages in terms of scale, brand recognition, and capital resources compared to larger, established players. Success will depend on its ability to carve out a niche and deliver a superior user experience.

Growth Trajectory and Initiatives

Historical Growth: Ainos Inc.'s historical growth trajectory may show periods of development and strategic repositioning. Analyzing revenue trends, user acquisition, and market penetration over recent years would provide a clearer picture of its past performance.

Future Projections: Future growth projections for Ainos Inc. would depend on analyst estimates, company guidance, and market conditions. Key drivers would include the adoption of its telehealth platform, expansion into new markets, and the success of its digital health initiatives.

Recent Initiatives: Recent strategic initiatives might include new product launches, partnerships with healthcare providers or technology companies, efforts to expand geographic reach, or investments in research and development to enhance its platform and services.

Summary

Ainos Inc. is positioning itself within the rapidly expanding telehealth and digital health sector. Its focus on remote patient care and digital solutions presents opportunities in a growing market. However, the company faces significant challenges from established competitors and requires substantial investment to scale effectively. Its future success hinges on its ability to innovate, secure partnerships, and gain market traction in a competitive landscape.

Similar Stocks

Sources and Disclaimers

Data Sources:

  • Company filings with the U.S. Securities and Exchange Commission (SEC)
  • Industry analysis reports
  • Financial news and data providers

Disclaimers:

This analysis is based on publicly available information and may not be exhaustive. Financial data and market share estimates are subject to change and are provided for informational purposes only. Investing in stocks carries inherent risks, and this information should not be construed as investment advice.

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Ainos Inc

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2013-11-04
CEO, President & Chairman of the Board Mr. Chun-Hsien Tsai
Sector Healthcare
Industry Medical Devices
Full time employees 44
Full time employees 44

Ainos, Inc., a dual-platform AI and biotech company, focusing SmellTech, AI diagnostics, and immune therapeutics. Its AI Nose platform uses a smell language model to digitize scent into Smell IDs and turning invisible chemical signals into machine-readable data. The company is also giving AI for robotics, smart factories, senior care, and women's health. In addition, it develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.